NURPF:OTC-Neuren Pharmaceuticals Limited (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 7.759

Change

0.00 (0.00)%

Market Cap

USD 1.01B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-11 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
ARGNF argenx SE

N/A

USD 39.01B
UCBJF UCB SA

N/A

USD 37.94B
UCBJY UCB SA ADR

N/A

USD 37.34B
GNMSF Genmab A/S

N/A

USD 13.64B
WXIBF WuXi Biologics

N/A

USD 8.99B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 8.93B
IVBIY IVBIY

N/A

USD 7.80B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 7.48B
ZLDPF Zealand Pharma A/S

N/A

USD 7.14B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.89B

ETFs Containing NURPF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.50% 55% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.50% 55% F 61% D-
Trailing 12 Months  
Capital Gain -49.83% 37% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.83% 37% F 21% F
Trailing 5 Years  
Capital Gain 345.92% 95% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 345.92% 95% A 94% A
Average Annual (5 Year Horizon)  
Capital Gain 102.78% 74% C 83% B
Dividend Return 102.78% 74% C 83% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 87.41% 49% F 38% F
Risk Adjusted Return 117.58% 100% F 99% N/A
Market Capitalization 1.01B 90% A- 73% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.